Get the Stockscreener App
3.39
2.87%
-0.10
Niagen Bioscience Inc stock is traded at $3.39, with a volume of 387.41K.
It is down -2.87% in the last 24 hours and down -2.31% over the past month.
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
See More
Previous Close:
$3.49
Open:
$3.48
24h Volume:
387.41K
Relative Volume:
0.47
Market Cap:
$269.99M
Revenue:
$130.42M
Net Income/Loss:
$18.64M
P/E Ratio:
15.54
EPS:
0.2182
Net Cash Flow:
$4.05M
1W Performance:
-1.17%
1M Performance:
-2.31%
6M Performance:
-48.01%
1Y Performance:
-71.25%
1-Day Range:
$3.39
$3.51
1-Week Range:
$3.33
$3.64
52-Week Range:
$3.175
$11.90
Niagen Bioscience Inc Stock (NAGE) Company Profile
Name
Niagen Bioscience Inc
Sector
Industry
Phone
310-388-6706
Address
10900 WILSHIRE BLVD, LOS ANGELES
Compare NAGE vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NAGE
Niagen Bioscience Inc
|
3.39 | 269.99M | 130.42M | 18.64M | 4.05M | 0.2182 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Niagen Bioscience Inc Stock (NAGE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-27-25 | Initiated | Canaccord Genuity | Buy |
| Aug-16-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-11-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Mar-08-22 | Initiated | ROTH Capital | Buy |
| Oct-16-19 | Initiated | Oppenheimer | Outperform |
| Feb-14-19 | Initiated | B. Riley FBR | Buy |
| Nov-27-17 | Resumed | H.C. Wainwright | Buy |
| Sep-25-17 | Initiated | Ladenburg Thalmann | Buy |
| Jan-03-17 | Initiated | Rodman & Renshaw | Buy |
View All
Niagen Bioscience Inc Stock (NAGE) Latest News
Niagen Bioscience Renames ChromaDex External Research Program to the Niagen Research Program, Strengthening Position as the Global Leader in NAD+ Science - AOL.com
Niagen Bioscience files prospectus to offer common stock up to $50M - scanx.trade
Form 424B5 Niagen Bioscience Inc For: 10 July By Investing.com - Investing.com South Africa
Canaccord reiterates Niagen Bioscience stock rating on drug launch By Investing.com - Investing.com Canada
Fed. Circ. Doubts $9M Atty Fees Without Dismissal Attempt - Law360
Niagen Bioscience (NASDAQ:NAGE) Stock Rating Upgraded by Freedom Capital - MarketBeat
Niagen Bioscience unveils NB-4168 for ataxia telangiectasia - BioWorld News
Niagen Bioscience CEO Rob Fried to Participate in Virtual Fireside Chat to Discuss Pharmaceutical Strategy on July 15, 2026 - Business Wire
Form 4 Niagen Bioscience Inc For: 8 July By Investing.com - Investing.com Nigeria
Niagen Bioscience (NAGE) CFO acquires stock through employee purchase plan - Stock Titan
Niagen Bioscience Launches Program to Develop Therapies for Accelerated Aging and Rare Genetic Diseases - marketscreener.com
Niagen Bioscience launches drug candidate for rare disease - Investing.com
Niagen Bioscience Launches Pharmaceutical Program for Accelerated Aging and Rare Genetic Diseases - Business Wire
Enterprise value to EBIT forward of Niagen Bioscience, Inc. – NASDAQ:NAGE - TradingView
Freedom Capital Markets Initiates Niagen Bioscience(NAGE.US) With Buy Rating, Announces Target Price $9 - Moomoo
Freedom Broker initiates Niagen Bioscience stock coverage with buy rating By Investing.com - Investing.com Nigeria
Freedom Broker initiates Niagen Bioscience stock coverage with buy rating - Investing.com
Implied Volatility Surging for Niagen Bioscience Stock Options - Zacks Investment Research
NAGENiagen Bioscience Inc Options - Finviz
H.C. Wainwright reiterates Niagen Bioscience stock rating on patent ruling By Investing.com - Investing.com India
Form S-3 Niagen Bioscience Inc For: 29 June By Investing.com - Investing.com Australia
Form 4 Niagen Bioscience Inc For: 26 June By Investing.com - Investing.com South Africa
Niagen Bioscience (NAGE) director receives 31,746 stock options at $3.45 strike - Stock Titan
Niagen Bioscience (NAGE) director awarded options for 31,746 shares at $3.45 strike - Stock Titan
Director at Niagen Bioscience (NAGE) receives 31,746 stock options award - Stock Titan
Niagen Bioscience (NAGE) director granted 31,746 stock options at $3.45 - Stock Titan
Niagen Bioscience (NAGE) director receives 31,746-share stock option grant at $3.45 - Stock Titan
Director Steven D. Rubin receives 31,746 Niagen Bioscience (NAGE) stock options - Stock Titan
Niagen Bioscience (NAGE) director receives grant of 31,746 stock options at $3.45 - Stock Titan
Niagen Bioscience Inc (NAGE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Price to book forward of Niagen Bioscience, Inc. – NASDAQ:NAGE - TradingView
NAGE Forecast — Price Target — Prediction for 2027 - TradingView
Niagen Bioscience, Inc. Actuals & Estimates (NASDAQ:NAGE) - TradingView
Enterprise value to revenue forward of Niagen Bioscience, Inc. – NASDAQ:NAGE - TradingView
Price to sales forward of Niagen Bioscience, Inc. – NASDAQ:NAGE - TradingView
Enterprise value to EBITDA forward of Niagen Bioscience, Inc. – NASDAQ:NAGE - TradingView
Niagen Bioscience Inc (NAGE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Niagen Bioscience Inc (NAGE) Valuation: PE, PB & Fair Value Analysis - TradingKey
Niagen Bioscience Renames Research Program to Advance NAD Cellular Health Studies - sekbernews.id
Niagen Bioscience Renames Research Program to Focus on NAD+ ApplicationsGuidance vs Actual - dars.gov.et
Niagen Bioscience Inc. (NAGE) Renames Research Program Amid Focus in Advancing NAD+ Applications - Insider Monkey
Niagen Bioscience Inc (NAGE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Niagen Bioscience Inc (NAGE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Niagen Bioscience Inc (NAGE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Niagen Bioscience Inc (NAGE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Niagen Bioscience Inc (NAGE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Niagen Bioscience Inc (NAGE) Institutional Confidence - TradingKey
Niagen Bioscience And 2 Other Promising Penny Stocks To Watch - simplywall.st
Niagen Bioscience (NAGE) Slips 1.14% as Stock Tests Key Support at $3.30OBV Breakout - dars.gov.et
Niagen Bioscience Q1 2026 slides: e-commerce surges 14% amid transition - Investing.com
Niagen Bioscience Inc Stock (NAGE) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):